Active — Not RecruitingNot Applicable

Eliminating Monitor Overuse Trial (EMO Trial)

United States, Canada9,265 participantsStarted 2021-12-01

Plain-language summary

The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.

Who can participate

Age range

2 Months

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Population a: Bronchiolitis patients directly observed while not receiving supplemental oxygen ("in room air," for primary trial outcome) Inclusion Criteria: * Infants and children 2 months through 23 months old * Hospitalized on non-ICU wards participating in the trial * Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine) * Primary diagnosis of bronchiolitis in most recent physician progress note * Not actively receiving supplemental oxygen ("in room air") * Last documented receipt of supplemental oxygen \>1 hour prior to direct observational data collection Exclusion Criteria: * Documented apnea or cyanosis during the current illness * Extreme prematurity (\<28 weeks completed gestation) * Cardiac disease * Pulmonary hypertension * Chronic lung disease * Home oxygen requirement * Neuromuscular disease * Immunodeficiency * Cancer * Severe Acute Respiratory Syndrome Coronavirus 2 (Covid-19 / SARS-CoV-2)-related illness (known or suspected, including multisystem inflammatory syndrome in children multi-system inflammatory syndrome in children (MIS-C) Population b: Bronchiolitis patients directly observed while receiving supplemental oxygen (for underuse evaluation). Inclusion Criteria: * Infants and children 2 months through 23 months old * Hospitalized on non-ICU wards participating in the trial * Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine) * Primary diagnosis of bronchiolitis in most recent…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Deimplementation Sustainment

Timeframe: Data from the baseline phase (approximately 7 months) was compared to data from the sustainment phase (approximately 4 months). Only data from baseline and sustainment phases are used in this calculation.

Trial details

NCT IDNCT05132322

SponsorChildren's Hospital of Philadelphia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-31

Results submitted2025-06-17

View on ClinicalTrials.gov More Bronchiolitis Acute Viral trials

Who can participate

Age range

2 Months

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.